Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 12 |
| List of Tables | 10 | 4 |
| List of Figures | 14 | 3 |
| Global Antivirals Market: Introduction | 17 | 1 |
| GBI Research Report Guidance | 17 | 1 |
| Global HIV Therapeutics Market: Overview | 18 | 2 |
| Disease Overview | 18 | 1 |
| Market Overview | 19 | 1 |
| Global HIV Therapeutics Market: Market Characterization | 20 | 19 |
| Market Forecasts | 20 | 1 |
| Annual Cost of Therapy | 21 | 2 |
| Usage Patterns | 23 | 1 |
| Diseased Population | 23 | 2 |
| Treatment Seeking Population | 25 | 2 |
| Diagnosis Population | 27 | 2 |
| Prescription Population | 29 | 2 |
| Usage Patterns | 31 | 2 |
| Geographical Distribution | 33 | 1 |
| HIV Therapeutics Market: Drivers and Restraints | 34 | 1 |
| Market Drivers | 34 | 1 |
| Increase in Awareness Levels of Disease Progression will Lead to Increase in Treatment Seeking and Diagnosed Population | 34 | 1 |
| Awareness in the US | 34 | 1 |
| Awareness in Europe | 34 | 1 |
| Awareness in Japan | 35 | 1 |
| New Product Launches with Better Efficacy will Drive the Market By Increasing Uptake | 35 | 1 |
| Increase in Drug Prices will Be a Key Driver for the Market by Driving Growth in the Next Few Years and Lowering the Impact of Generics | 36 | 1 |
| Inflation and Drug Prices | 36 | 1 |
| HIV Therapy and Switch to New Drugs | 36 | 1 |
| Market Restraints | 37 | 1 |
| Patent Expirations and the Subsequent Entry of Generics will Impact the Market Negatively as Some People will Move to Generic Versions | 37 | 1 |
| Social Stigma Associated with HIV Leads to Low Rate of Treatment Seeking Thus Impacting the Overall Customer Base | 38 | 1 |
| Rigorous and Complex Treatment Regimes for Most HIV Therapies Result in Poor Patient Compliance Leading to a Reduction in Drug Volumes | 38 | 1 |
| Global HIV Therapeutics Market: The US Market | 39 | 12 |
| Market Forecasts | 39 | 2 |
| Annual Cost of Therapy | 41 | 1 |
| Usage Patterns | 42 | 1 |
| Diseased Population | 42 | 2 |
| Treatment Seeking Population | 44 | 1 |
| Diagnosis Population | 45 | 2 |
| Prescription Population | 47 | 2 |
| Usage Patterns | 49 | 2 |
| Global HIV Therapeutics Market: Europe Market | 51 | 12 |
| Market Forecasts | 51 | 2 |
| Annual Cost of Therapy | 53 | 2 |
| Usage Patterns | 55 | 1 |
| Diseased Population | 55 | 1 |
| Treatment Seeking Population | 56 | 2 |
| Diagnosis Population | 58 | 2 |
| Prescription Population | 60 | 1 |
| Usage Patterns | 61 | 2 |
| Global HIV Therapeutics Market: Japan Market | 63 | 9 |
| Market Forecasts | 63 | 2 |
| Annual Cost of Therapy | 65 | 1 |
| Usage Patterns | 66 | 1 |
| Diseased Population | 66 | 1 |
| Treatment Seeking Population | 67 | 1 |
| Diagnosis Population | 68 | 1 |
| Prescription Population | 69 | 1 |
| Usage Patterns | 70 | 2 |
| Global HIV Therapeutics Market: Major Drug Classes | 72 | 33 |
| Different Classes of Drugs | 72 | 1 |
| Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) | 72 | 1 |
| Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs) | 73 | 1 |
| Protease Inhibitors | 74 | 1 |
| Viral Fusion (or Entry) Inhibitors | 74 | 1 |
| HIV Integrase Strand Transfer Inhibitors | 74 | 1 |
| Multi-class Combination Products | 74 | 1 |
| Pipeline Analysis | 75 | 1 |
| Phase I | 76 | 8 |
| Phase II | 84 | 13 |
| Phase III | 97 | 8 |
| Global Hepatitis Therapeutics Market: Market Overview | 105 | 12 |
| Introduction | 105 | 1 |
| Revenue Forecasts for the Global Hepatitis Therapeutics Market | 106 | 1 |
| Sales Value | 106 | 1 |
| Annual Cost of Therapy | 107 | 1 |
| Treatment Usage Patterns | 108 | 2 |
| Diseased Population | 110 | 1 |
| Treatment Seeking Population | 111 | 1 |
| Diagnosed Population | 112 | 1 |
| Prescription Population | 113 | 1 |
| Hepatitis Market Drivers | 114 | 1 |
| Hepatitis C is a Growing Market with Strong Competition and a Promising Pipeline | 114 | 1 |
| Promising Developments in the Hepatitis C Pipeline | 114 | 1 |
| Steady Increase in Prescription Population | 114 | 1 |
| Hepatitis Market Restraints | 115 | 1 |
| Hepatitis is Rarely Recognized During the Early Stages of the Disease Due to Lack of Symptoms During the Acute Phase | 115 | 1 |
| Low Treatment Seeking Population | 115 | 1 |
| Loss of Exclusivity Protection in Hepatitis B Market | 115 | 1 |
| Generic Share in the Global Hepatitis Market | 116 | 1 |
| Global Hepatitis Market: Therapeutic Landscape | 117 | 24 |
| Introduction | 117 | 1 |
| Hepatitis A | 117 | 1 |
| Hepatitis B | 117 | 1 |
| Overview of Hepatitis A and B Vaccines Market | 117 | 1 |
| Sales Value | 118 | 1 |
| Hepatitis B Market | 119 | 1 |
| Introduction | 119 | 1 |
| Sales Value | 120 | 1 |
| Annual Cost of Therapy | 121 | 1 |
| Treatment Usage Patterns | 122 | 1 |
| Diseased Population | 123 | 1 |
| Treatment Seeking Population | 124 | 1 |
| Diagnosed Population | 125 | 1 |
| Prescription Population | 126 | 1 |
| Geographical Segmentation | 127 | 2 |
| Hepatitis C Market | 129 | 1 |
| Introduction | 129 | 1 |
| Sales Value | 130 | 1 |
| Annual Cost of Therapy | 131 | 1 |
| Treatment Usage Patterns | 132 | 2 |
| Diseased Population | 134 | 1 |
| Treatment Seeking Population | 135 | 1 |
| Diagnosed Population | 136 | 1 |
| Prescription Population | 137 | 1 |
| Geographical Segmentation | 138 | 3 |
| Global Hepatitis Market: Geographical Landscape | 141 | 50 |
| Geographical Break-up | 141 | 3 |
| The US | 144 | 1 |
| Sales Value | 144 | 1 |
| Annual Cost of Therapy | 145 | 1 |
| Treatment Usage Patterns | 146 | 2 |
| Diseased Population | 148 | 1 |
| Treatment Seeking Population | 149 | 1 |
| Diagnosed Population | 150 | 1 |
| Prescription Population | 151 | 1 |
| Top Five Countries in Europe | 152 | 1 |
| Sales Value | 152 | 2 |
| Annual Cost of Therapy | 154 | 1 |
| Treatment Usage Patterns | 155 | 1 |
| Diseased Population | 156 | 1 |
| Treatment Seeking Population | 157 | 1 |
| Diagnosed Population | 158 | 1 |
| Prescription Population | 159 | 1 |
| Japan | 160 | 1 |
| Sales Value | 160 | 1 |
| Annual Cost of Therapy | 161 | 1 |
| Treatment Usage Patterns | 162 | 2 |
| Diseased Population | 164 | 1 |
| Treatment Seeking Population | 165 | 1 |
| Diagnosed Population | 166 | 1 |
| Prescription Population | 167 | 1 |
| Global Hepatitis Vaccines and Therapeutics Market: Pipeline Analysis | 168 | 1 |
| Introduction | 168 | 3 |
| Research and Development Pipeline Hepatitis B Therapeutics | 171 | 5 |
| Research and Development Pipeline Hepatitis C Therapeutics | 176 | 15 |
| Herpes Simplex Therapeutics Market: Market Characterization | 191 | 10 |
| Overview | 191 | 1 |
| Herpes Simplex Therapeutics Market Size | 192 | 1 |
| Herpes Simplex Therapeutics Market Forecast and CAGR | 193 | 1 |
| Drivers and Barriers for the Herpes Simplex Therapeutics Market | 194 | 1 |
| Drivers for the Herpes Simplex Therapeutics Market | 194 | 1 |
| Barriers for the Herpes Simplex Therapeutics Market | 194 | 1 |
| Herpes Simplex Therapeutics Market: Competitive Assessment | 195 | 1 |
| Overview | 195 | 1 |
| Strategic Competitor Assessment | 195 | 1 |
| Product Portfolio for Major Marketed Products in the Herpes Simplex Therapeutics Market | 196 | 1 |
| Zovirax (Acyclovir) | 196 | 1 |
| Overview | 196 | 1 |
| Efficacy | 196 | 1 |
| Safety | 196 | 1 |
| Clinical Study Details | 196 | 1 |
| Famvir (Famciclovir) | 197 | 1 |
| Overview | 197 | 1 |
| Efficacy | 197 | 1 |
| Safety | 197 | 1 |
| Clinical Study Details | 197 | 1 |
| Valtrex (Valacyclovir) | 198 | 1 |
| Overview | 198 | 3 |
| Herpes Simplex Therapeutics Market: Pipeline Assessment | 201 | 6 |
| Overview | 201 | 1 |
| Herpes Simplex Therapeutics Promising Drugs under Clinical Development | 201 | 1 |
| Molecule Profiles for Promising Drugs under Clinical Development | 201 | 1 |
| BA-021 (Acyclovir Lauriad) | 201 | 1 |
| Overview | 201 | 1 |
| Efficacy | 201 | 1 |
| Safety | 201 | 1 |
| Clinical Study Details | 201 | 1 |
| RPI-78M | 202 | 1 |
| Overview | 202 | 1 |
| Efficacy | 202 | 1 |
| Safety | 202 | 1 |
| Clinical Study Details | 202 | 1 |
| AIC316 | 202 | 1 |
| Overview | 202 | 1 |
| Efficacy | 202 | 1 |
| Safety | 202 | 1 |
| Clinical Study Details | 202 | 1 |
| Herpes Simplex Therapeutics Market Pipeline Assessment by Mechanism of Action | 203 | 1 |
| Herpes Simplex Therapeutics Market Pipeline Assessment by Clinical Phase of Development | 204 | 1 |
| Herpes Simplex Therapeutics Phase III Clinical Pipeline | 204 | 1 |
| Herpes Simplex Therapeutics Phase II Clinical Pipeline | 205 | 1 |
| Herpes Simplex Therapeutics Phase I Clinical Pipeline | 205 | 1 |
| Herpes Simplex Therapeutics Preclinical Pipeline | 206 | 1 |
| Global Influenza Therapeutics Market: Overview | 207 | 2 |
| Disease Overview | 207 | 1 |
| Influenza | 207 | 1 |
| Market Overview | 208 | 1 |
| Global Influenza Therapeutics Market: Market Characterization | 209 | 7 |
| Market Forecasts | 209 | 1 |
| Annual Cost of Therapy | 210 | 1 |
| Usage Patterns | 211 | 1 |
| Diseased Population | 211 | 1 |
| Treatment Seeking Population | 212 | 1 |
| Diagnosis Population | 213 | 1 |
| Usage Patterns | 214 | 1 |
| Geographical Distribution | 215 | 1 |
| Global Influenza Therapeutics Market: The US Market | 216 | 8 |
| Market Forecasts | 216 | 1 |
| Annual Cost of Therapy | 217 | 1 |
| Usage Patterns | 218 | 1 |
| Diseased Population | 218 | 1 |
| Treatment Seeking Population | 219 | 1 |
| Diagnosis Population | 220 | 1 |
| Prescription Population | 221 | 1 |
| Usage Patterns | 222 | 2 |
| Global Influenza Therapeutics Market: Europe Market | 224 | 8 |
| Market Forecasts | 224 | 1 |
| Annual Cost of Therapy | 225 | 1 |
| Usage Patterns | 226 | 1 |
| Diseased Population | 226 | 1 |
| Treatment Seeking Population | 227 | 1 |
| Diagnosis Population | 228 | 1 |
| Prescription Population | 229 | 1 |
| Usage Patterns | 230 | 2 |
| Global Influenza Therapeutics Market: Japan Market | 232 | 8 |
| Market Forecasts | 232 | 1 |
| Annual Cost of Therapy | 233 | 1 |
| Usage Patterns | 234 | 1 |
| Diseased Population | 234 | 1 |
| Treatment Seeking Population | 235 | 1 |
| Diagnosis Population | 236 | 1 |
| Prescription Population | 237 | 1 |
| Usage Patterns | 238 | 2 |
| Pipeline Analysis | 240 | 7 |
| Phase I | 240 | 1 |
| CS-8958 | 241 | 1 |
| GSK 2115160A | 241 | 1 |
| Oseltamivir+Zanamivir | 241 | 1 |
| Poly ICLC | 241 | 1 |
| VAX128C | 241 | 1 |
| Phase II | 242 | 1 |
| ADS-8902 | 242 | 1 |
| Chloroquine | 242 | 1 |
| CSL-412 | 243 | 1 |
| DeltaFLU | 243 | 1 |
| Fludase | 243 | 1 |
| MVA-NP+M1 | 243 | 1 |
| Oseltamivir | 243 | 1 |
| TCAD Therapy | 244 | 1 |